Charles River Laboratories (CRL) to Report Q4 Earnings: Revenue Forecast Dip

Charles River Laboratories (NYSE:CRL) will release Q4 earnings before the market opens on Wednesday, February 17, 2026. Analysts expect revenue of $980.9 million, down 2.2% year-over-year, with adjusted EPS of $2.35. Last quarter, CRL reported $1.00 billion in revenue, flat year-over-year, slightly beating consensus. Over the past year, the stock declined 26.1% amid industry headwinds and policy uncertainty. Peers Medpace and West Pharmaceutical Services posted strong results, with Medpace's shares falling 15.9% post-earnings and West's rising 1.8%.